Clinical Trial Update: Thalidomide to Treat Oral Lesions in HIV-Infected Patients [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluated thalidomide for treating oral lesions in HIV/AIDS patients; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Immunodeficiency Syndrome
• Burning Mouth Syndrome
• HIV Infection

Drugs mentioned

• Thalidomide (thalidomide)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Acquired Immunodeficiency Syndrome, Burning Mouth Syndrome | Phase 2 | Status: COMPLETED